Targets › HYAL1
1 program from 1 company in 1 trial: 1 Phase 2; Neurology; next expected readout Jun 2027.
May have a role in promoting tumor progression. May block the TGFB1-enhanced cell growth. (UniProt, Q12794)
Open in Phaseline: the race on HYAL1, likelihood bands and readouts
| Company | Drug | Targets | Highest phase | Conditions | Next expected readout |
|---|---|---|---|---|---|
| Johns Hopkins University | Hyaluronidase (HYLENEX recombinant) Hyaluronidase enzyme that hydrolyzes hyaluronic acid in the extracellular matrix to reduce | HYAL1 | Phase 2 | Muscle Spasticity | Jun 2027 |
Muscle Spasticity (1)
protein or peptide (1)
Johns Hopkins University (1)
–
Programs group each company's trials by drug; targets and mechanisms come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood is in the app.